|
|
SITC Advances in Cancer Immunotherapy™ Online Courses
ACI 2023 Online Interactive eLearning Courses: The ACI 2023 interactive eLearning modules are designed to cover the foundational and other concepts that we could not cover extensively in the live webinars. These modules are free for everyone.
ACI 2021-2022 Online Interactive Courses & Accredited Webinars: For ACI 2021-2022 Online Interactive Courses & Accredited Webinars: The 2021-2022 ACI webinars are designed for those who were not able to attend the live program, but still want to view the content, Q&A and panel discussions and receive credit for their attendance. As an added benefit, three additional interactive CE- courses (Introduction to Immunotherapy, Mechanisms of IrAEs, and Toxicity Management) are offered to provide a thorough and interactive dive into these foundational concepts at no cost. |
 | Published Date: 06/30/2023
Expiration Date: 06/30/2024
Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).
The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Introduction to Biomarkers provides an overview on types of biomarkers and its significance in treatment of cancer. The SME has discussed various findings and outcomes of the clinical trial initiatives related to biomarkers.
View all available ACI online offerings at www.sitcancer.org/acionline.
Estimated time to complete the activity: 45 minutes
For additional information about the accreditation of this activity, please visit https://partnersed.com
Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Target Audience
This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.
Educational Objectives:
Upon completion of this activity, participants should be able to:
- Define the term biomarker.
- Explain the functions of biomarkers.
- Differentiate the biomarkers based on their types.
- Describe the use of biomarkers in various cancer treatments.
- Summarize the challenges of using biomarkers in the treatment of cancer.
Faculty and Disclosure of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty:
Dr. Paolo A. Ascierto, MD
Director of Department of Melanoma
UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative
Istituto Nazionale Tumori – Fondazione “G. Pascale”
Napoli, Italy
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Conflicts of Interest:
Researcher: Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi
Consultant/Advisor/Speaker: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Joint Accreditation Statement
 In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.
Pharmacy Continuing Education
PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-23-162-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Instructions for Credit
During the period 06/30/2023 through 06/30/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: June 30, 2023
On-Demand Release Date: Available Now |
Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
| Published Date: 06/01/2023
Expiration Date: 06/01/2024
Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).
The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.
View all available ACI online offerings at www.sitcancer.org/acionline.
Estimated time to complete the activity: 45 minutes
For additional information about the accreditation of this activity, please visit https://partnersed.com
Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Target Audience
This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.
Educational Objectives:
Upon completion of this activity, participants should be able to:
- Explain the Mechanisms of immune related Adverse Events in brief.
- Describe the other host factors that affect the risk of immune related Adverse Events.
- Summarize the differences in PD-L1 and CTLA-4 toxicities.
- Explain the response assessment process in a patient for the immunotherapy treatment.
Faculty and Disclosure of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty:
Pradnya Patil, MD, FACP
Associate Staff Oncologist
Taussig Cancer Center, Cleveland Clinic
Cleveland, OH
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Conflicts of Interest:
Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.
Pharmacy Continuing Education
PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-23-151-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Instructions for Credit
During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: May 30, 2023
On-Demand Release Date: Available Now |
Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| Published Date: 05/05/2023
Expiration Date: 05/05/2024
Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).
The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team. The ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.
This course, Introduction to Immunology provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.
View all available ACI online offerings at www.sitcancer.org/acionline.
Estimated time to complete the activity: 1 hour
For additional information about the accreditation of this activity, please visit https://partnersed.com
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Target Audience
This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.
Educational Objectives:
Upon completion of this activity, participants should be able to:
- Describe the function of the components of the immune system, including relevant cells, molecules, and organs of the immune system.
- Differentiate between the adaptive immune system and the innate immune system.
- Recognize the barriers to effective immunotherapy, including mechanism by which tumors locally disable and/or evade the immune system.
Faculty and Disclosure of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty:
Chrystal M. Paulos, PhD
Director of Translational Research, Cutaneous Malignancies
Winship Cancer Institute at Emory University
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Conflicts of Interest:
IP Rights: Ares Immunotherapy
Consulting Fees: Ares Immunotherapy
Founder/Owner: Ares Immunotherapy
Other (subcontracts): Obsidian, Lycera, ThermaFisher
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Pharmacy Continuing Education
PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-23-142-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Instructions for Credit
During the period 05/05/2023 through 05/05/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: May 05, 2023
On-Demand Release Date: Available Now |
Approved Credit: : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ANCC: 1 hour Contact HourACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ACPE: 1 hour Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| Published: On 04/28/2023
Please note, this activity does not offer continuing education credit.
The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.
Additional support for this activity provided by:
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.
This course, Basic Principles of Cancer Immunotherapy will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.
View all available ACI online offerings at www.sitcancer.org/acionline.
Estimated time to complete activity: 1 hour
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the concept of Immunotherapy.
- Identify the various types of cancer immunotherapy.
- Describe the rationale for common approaches to cancer immunotherapy.
- Explain the response assessment process in a patient for the immunotherapy treatment.
Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.
Faculty
Christian M. Capitini, MD
Associate Professor
University of Wisconsin-Madison
Disclosure of Conflicts of Interest
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Christian M. Capitini, MD: Works at a Academic Medical Center and a consultant advisor speaker for Bayer, Elephas, Novartis, Nektar Therapeutics, WiCell Research Institute
The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
| | Original Course Date: April 28, 2023
|
Approved Credit: CoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| Published: On 08/11/2023
Please note, this activity does not offer continuing education credit.
The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.
Additional support for this activity provided by:
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.
The course- Combination therapies in Combating Cancer gives a brief overview of the several combination therapies such as Inhibitory Immune Checkpoint Combination therapy, Targeted Immunotherapy approches, and other emerging combination therapies. In this course, the subject matter expert describes the effectiveness of various combination immunotherpy approches and their outcomes in cancer patients using several case studies and research papers. The course content emphasizes the emerging landscape of combining immunotherapy with different modalities to treat cancer.
View all available ACI online offerings at www.sitcancer.org/acionline.
Estimated time to complete activity: 1 hour
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe key immunotherapy targets that are useful for combination approaches.
- Describe immunotherapy-based combination treatment regimens currently under investigation.
- Discuss the emerging landscape of combining immunotherapy with different modalities to treat cancer.
Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.
Faculty
Gregory B. Lesinski, PhD, MPH
Co-Director, Translational GI Malignancy Program
Winship Cancer Institute of Emory University,
Atlanta, Georgia, USA
Disclosure of Conflicts of Interest
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Gregory B. Lesinski, PhD, MPH: Works at a Academic Medical Center and a consultant advisor speaker for Bristol-Myers Squib, Vaccinex, Boerhinger-Ingelheim, Merck and Co.
The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
| | Original Course Date: March 02, 2023
|
Approved Credit: CoP: 0.00 hours Certificate of Participation
| | MORE INFO |
|
| Published 12/21/2022
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This interactive course, Toxicity Management provides information on incidence, onset, severity, and grading of immune-related toxicities and irAEs with immune checkpoint inhibitors. Dr. Alexa Meara and Dr. Pankti Reid have also presented cases focussing irAEs, treatment plan, and management.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: December 21, 2022 - December 21, 2023
Estimated time to complete activity: 90 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the end of this activity, the participant should be able to:
- Identify immune-related toxicities by grade, onset, and incidence.
- Identify immune-related adverse events resulting from immune checkpoint inhibitors.
- Describe the adverse events and management of cellular therapies.
- Describe the precautions needed when immunotherapy is provided to special patient populations.
Faculty
Alexa S. Meara, MD
Associate Professor
Division of Oncology
Division Rheumatology and Immunology
The Ohio State Wexner Medical Center, Ohio
Pankti Reid, MD, MPH
Assistant Professor
University of Chicago Medical Center, Illinois
Department of Medicine- Division of Rheumatology
Committee on Clinical Pharmacology and Pharmacogenomics
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Alexa Meara, MD - Consultant/Advisor/Speaker: Abbvie, GSK, Amgen, Sanofi, Aurinia
Pankti Reid, MD - Royalty and Patent Beneficiary: Patent pending for use of interleukin 6 axis inhibitor for viral infection associated pneumonitis
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 12/21/2022 through 12/21/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
 In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hour. Designated for 1 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (1.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-494-H01-P
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: December 21, 2022
|
Approved Credit: : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™ANCC: 1.50 hours Contact HourACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™ACPE: 1.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 5/20/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Immune Checkpoint Inhibitors. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: May 20, 2022 - May 20, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Marina Chiara Garassino, MD - The University of Chicago
Natalie Vokes, MD - The University of Texas MD Anderson Cancer Center
Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre, Dublin
Diane Tseng, MD, PhD - University of Washington School of Medicine, Fred Hutchinson Cancer Research Center
Bonnie Bermas, MD - UT Southwestern Medical Center
Vickie Shannon, MD - The University of Texas MD Anderson Cancer Center
Sadia Ali, MD - UT Southwestern Medical Center
Nikhil I. Khushalani, MD - Moffitt Cancer Center
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the mechanisms of immune checkpoint inhibitors.
- Summarize recent updates in the use of immune checkpoint inhibitors clinically.
- Outline common toxicities with immune checkpoint inhibitors and their management.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-240-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: April 23, 2022
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published May 23, 2022
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This interactive course provides an overview of the mechanisms of immune-related adverse events (irAEs) that may be caused by implementing cancer immunotherapy. This module walks the learner through the various mechanisms of irAEs, as well as differentiating early and late irAEs which may be distinguished by distinct mechanisms. Learners will also have the opportunity to apply the knowledge gained in this module through two case studies.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: May 23, 2022 - May 23, 2023
Estimated time to complete activity: 15 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the various mechanisms of irAEs as well as the types of irAEs that may result.
- Describe various irAEs as well as treatment for severe irAEs.
- Differentiate central vs. peripheral tolerance of irAEs.
Faculty
Pradnya Patil, MD, FACP
Associate Staff / Department of Hematology-Oncology
Cleveland Clinic, Cleveland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Pradnya Patil, MD, FACP - Nothing to disclose.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period May 23, 2022 through May 23, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-279-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: March 16, 2022
|
Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 3/24/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Skin Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: March 24, 2022 - March 24, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Allison Betof Warner, MD, PhD - Memoral Sloan Kettering Cancer Center
Isabella C. Glitza, MD, PhD - The University of Texas MD Anderson Cancer Center
Janice Mehnert, MD - NYU Langone Health
Michael K. Wong - MD, PhD - The University of Texas MD Anderson Cancer Center
Ryan J. Sullivan, MD - Harvard Medical School, Massachusetts General Hospital
Omid Hamid, MD - The Angeles Clinic and Research Institute
Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre Dublin
Kathy Madden, NP, RN, MSN, FNP-BC, AOCNP, APHN - NYU Langone Perlmutter Cancer Center
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in use for the treatment of skin cancers.
- Summarize recent updates in cancer immunotherapy for skin cancers, including emerging toxicities and managment.
- Implement cancer immunotherapy for skin cancer into clinical pratice appropriately.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-130-H01-P
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: February 24, 2022
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 2/24/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Intratumoral Therapies, Vaccines, and Cytokines. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: February 24, 2022 - February 24, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Diwakar Davar, MMBBS, MSc - UPMC Hillman Cancer Center
Patrick Ott, MD, PhD - Dana Farber Cancer Institute
Adi Diab, MD - The University of Texas MD Anderson Cancer Center
Harriet Kluger, MD - Yale School of Medicine
Matthew J. Frigault, MD, MSc - Massachusetts General Hospital
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.
- Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically.
- Outline common toxicities with intratumoral therapies, vaccines, and cytokines, and their management.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-073-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: January 27, 2022
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 2/9/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Head and Neck Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: February 9, 2022 - February 9, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Jessica R. Bauman, MD - Fox Chase Cancer Center
Jessica L. Geiger, MD - Cleveland Clinic Cancer Center
Dan P. Zandberg, MD - UPMC Hillman Cancer Center
Tanguy Seiwert, MD - Johns Hopkins Medicine
Trisha Wise-Draper, MD, PhD - University of Cincinnati Cancer Center
Ranee Mehra, MD - University of Maryland
Ravindra Uppaluri, MD, PhD - Dana Farber Cancer Institute and Brigham and Women's Hospital
Sana Karam, MD, PhD - University of Colorado
Aarti Bhatia, MD - Yale School of Medicine
Sid Sheth, MD - UNC School of Medicine
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in the use for the treatment of head and neck cancers.
- Summarize recent updates in cancer immunotherapy for head and neck cancers as well as toxicity management for key disease states.
- Implement cancer immunotherapy for head and neck cancers into clinical practice appropriately.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-052-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: January 12, 2022
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 3/15/2022
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: March 15, 2022 - March 15, 2023
Estimated time to complete activity: 30 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Implement cancer immunotherapy treatment for cancer.
- Identify the various types and appropriate use of cancer immunotherapy.
- Describe the rationale for common approaches to cancer immunotherapy.
Faculty
Christian Capitini, MD
Associate Professor of Pediatrics Hematology/Oncology
University of Wisconsin - Madison
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Christian Capitini, MD - Consulting Fees: Nektar Therapeutics; Novartis; Elephas Bio
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 3/15/2022 through 03/15/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.3 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-110-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: December 22, 2021
|
Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 2/9/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Cell Therapies and T Cell Engagers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: February 9, 2022 - February 9, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Loretta Nastoupil, MD - The University of Texas MD Anderson Cancer Center
Tycel J. Phillips, MD - University of Michigan Health
Krina K. Patel, MD, MSc - The University of Texas MD Anderson Cancer Center
Hans Lee, MD - The University of Texas MD Anderson Cancer Center
Joanna C. Yang, MD, MPH - Washington University
Chelsea C. Pinnix, MD, PhD - The University of Texas MD Anderson Cancer Center
Yi Lin, MD, PhD - Mayo Clinic
Tania Jain, MBBS - Johns Hopkins University
Zainab Shahid, MD, FACP - University of North Carolina at Chapel Hill
Surbhi Sidana, MD - Stanford University
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the mechanisms of cell therapies and T cell engagers.
- Summarize recent updates in the use of cell therapies and T cell engagers clinically.
- Outline common toxicities with cell therapies and T cell engagers and their management
- Identify unique institutional resources required for the appropriate use of cell therapies.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-045-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: December 18, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 2/9/22
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Gynecologic Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: February 9, 2022 - February 9, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Amy Bregar, MD - Massachusetts General Hospital
Roisin O'Cearbhaill, MD - Memorial Sloan Ketting Cancer Center
Mary L. Disis, MD, FACP - Univerisity of Washington
Kerry Reynolds, MD - Massachusetts General Hospital
Shannon Westin, MD - MD Anderson Cancer Center
Emese Zsiros, MD, PhD - Rosewell Park Cancer Institute
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in use for the treatment of gynecologic cancers.
- Summarize recent updates in cancer immunotherapy for gynecologic cancers including emerging toxicities and management.
- Implement cancer immunotherapy for gynecologic cancer into clinical practice appropriately.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-104-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: December 14, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 4/21/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Biomarkers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: April 21, 2022 - April 21, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Allen Gown, MD - University of British Columbia
Andrew Coveler, MD - University of Washington / Fred Hutchinson Cancer Research Center
Eric Konnick, MD, MS - University of Washington
Nora Disis, MD, FACP - University of Washington
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Discuss biomarkers in clinical use with approved cancer immunotherapies.
- Summarize recent updates in the use of biomarkers for cancer immunotherapies.
- Implement the use of biomarkers to select appropriate treatments for patients with cancer.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-236-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 5/26/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Toxicity Management. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: May 26, 2022 - May 26, 2023
Estimated time to complete activity: 4.0 hours
Faculty:
Noha Abdel-Wahab, MD, PhD - The University of Texas MD Anderson Cancer Center
Adi Diab, MD - The University of Texas MD Anderson Cancer Center
Van Anh Trinh, PharmD - The University of Texas MD Anderson Cancer Center
Sumit Subudhi, MD, PhD - The University of Texas MD Anderson Cancer Center
Mehmet Altan, MD - The University of Texas MD Anderson Cancer Center
Nicolas L. Palaskas, MD - The University of Texas MD Anderson Cancer Center
Yinghong Wang, MD, PhD, MSc - The University of Texas MD Anderson Cancer Center
Maen Abdelrahim, MD, PhD, PharmD - Houston Methodist
Jennifer A. Wargo, MD, MMSc - The University of Texas MD Anderson Cancer Center
Michelle Rohlfs, APRN, FNP-BC, AOCNP - The University of Texas MD Anderson Cancer Center
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify appropriate clinical management of common immune-related adverse events resulting from cancer immunotherapy treatments, including immune checkpoint inhibitors and cell therapies.
- Outline the best practices for multidisciplinary management of patients receiving cancer immunotherapy treatment.
- Describe management approaches for difficult or refractory immune-related adverse events.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 4.0 contact hours. Designated for 2.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 4.0 contact hours (0.4 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-241-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 4.00 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 4.00 hours AMA PRA Category 1 Credit(s)™ANCC: 4.00 hours Contact HourACCME (MD/DO): 4.00 hours AMA PRA Category 1 Credit(s)™ACPE: 4.00 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 4/6/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Breast Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: April 6, 2022 - April 6, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Leisha Emens, MD, PhD - University of Pittsburgh
Daniel Stover, MD - The Ohio State University
Ashley Cimino-Mathews, MD - Johns Hopkins University
Laura Kennedy, MD, PhD - Vanderbilt University
Sagar Sardesai, MBBS - The Ohio State University
Margaret Gatti-Mays, MD, MPH – Ohio State University Comprehensive Cancer Center
Melissa Wilson, PA-C, MPAS - University of Pittsburgh
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in use for the treatment of breast cancers.
- Summarize recent updates in cancer immunotherapy for breast cancers including emerging toxicities and management.
- Implement cancer immunotherapy for breast cancer into clinical practice appropriately.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 2.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-184-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 3/2/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Hematologic Malignancies. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: March 2, 2022 - March 2, 2023
Estimated time to complete activity: 3.75hours
Faculty:
Nina Shah, MD - University of California San Francisco
Surbhi Sidana, MD - Stanford University
Aaron Logan, MD, PhD - University of California San Francisco
Naval Daver, MD - The University of Texas MD Anderson Cancer Center
Michael Spinner, MD - Stanford University
Charalambos (Babis) Andreadis, MD, MSCE - University of California San Francisco
Samantha Shenoy, NP - UCSF Medical Center
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in use for the treatment of hematologic malignancies.
- Summarize recent updates in cancer immunotherapy for hematologic malignancies, including emerging toxicities and management
- Implement cancer immunotherapy for hematologic malignancies into clinical practice appropriately.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.75 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-078-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 5/3/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Lung Cancer. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: May 3, 2022 - May 3, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Anne Chiang, MD, PhD -- Yale School of Medicine
Marianne Davies, NP, DNP, MSN, BSN --Yale School of Nursing
Roy S. Herbst, MD, PhD -- Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital
Hossein Borghaei, DO, MS -- Fox Chase Cancer Center
Mark Awad, MD, PhD -- Dana-Farber Cancer Institute
Sarah Goldberg, MD, MPH -- Yale School of Medicine
Henry S. Park, MD, MPH -- Yale School of Medicine
Scott N. Gettinger, MD -- Yale School of Medicine
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify cancer immunotherapy approaches in use for the treatment of lung cancers.
- Summarize recent updates in cancer immunotherapy for lunch cancers including emerging toxicities and management.
- Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
- Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-239-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 3/10/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Monoclonal Antibodies and Antibody-Drug Conjugates. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: March 10, 2022 - March 10, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Komal Jhaveri, MD, FACP - Memorial Sloan Kettering Cancer Center
Nina Shah, MD - University of California San Francisco
David Ilson, MD, PhD - Memorial Sloan Kettering Cancer Center
Daniel Petrylak, MD - Yale School of Medicine
Patrick Brown, MD - Johns Hopkins University
Aditya Bardia, MD, MPH - Massachusetts General Hospital
Christian M. Captini, MD - University of Wisconsin-Madison
Hope Rugo, MD - University of California San Francisco Comprehensive Care Center
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the mechanisms of monoclonal antibodies and antibody-drug conjugates.
- Summarize recent updates in the use of monoclonal antibodies and antibody-drug conjugates clinically.
- Outline common toxicities with monoclonal antibodies and antibody-drug conjugates and their management.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-079-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 2/9/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Gastrointestinal Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: February 9, 2022 - February 9, 2023
Estimated time to complete activity: 3.25 hours
Faculty:
Ghassan K. Abou-Alfa, MD, MBA - Memorial Sloan Kettering Cancer Center
Arndt Vogel, MD - Medizinische Hochschule, Hannover, Germany
James J. Harding, MD - Memorial Sloan Kettering Cancer Center
Stephen L. Chan, MBBS, FRCP -The Chinese University of Hong Kong
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in use for the treatment of gastrointestinal cancers.
- Summarize recent updates in cancer immunotherapy for gastrointestinal cancers including emerging toxicities and management.
- Implement cancer immunotherapy for gastrointestinal cancer into clinical practice appropriately.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.25 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.25 contact hours (0.325 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-006-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 3.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.25 hours AMA PRA Category 1 Credit(s)™ANCC: 3.25 hours Contact HourACCME (MD/DO): 3.25 hours AMA PRA Category 1 Credit(s)™ACPE: 3.25 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 2/9/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on MSI-High and TMB-High Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: February 9, 2022 - February 9, 2023
Estimated time to complete activity: 3.75 hours
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.
- Summarize recent updates in cancer immunotherapy for MSI-H/TMB-H cancers and toxicity management for key disease states.
- Implement cancer immunotherapy for MSI-H/TMB-H cancer into clinical practice appropriately.
- Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.
Faculty
Young Kwang Chae, MD, MPH, MBA - Northwestern University
Daniel McGrail, PhD - The University of Texas MD Anderson Cancer Care Center
Zsofia Stadler, MD - Memorial Sloamn Kettering Cancer Center
John Strickler, MD - Duke University Medical Center
Nicholas DeVito, MD - Duke University Hospital
Funda Meric-Bernstam, MD - The University of Texas MD Anderson Cancer Care Center
Neil Segal, MD, PhD - Memorial Sloamn Kettering Cancer Center
Mohamed Salem, MD - Atrium Health
Theresa Brown, PharmD, BCOP - Duke University Hospital
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-008-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: November 03, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
| This course is no longer available for credit.
Published 2/9/2022
Course Description
This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Genitourinary Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Funders Statement
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.
Credit Available: February 9, 2022 - February 9, 2023
Estimated time to complete activity: 3.75 hours
Faculty:
Jessica Clement, MD - Hartford Healthcare
Alexandra Drakaki, MD, PhD - UCLA
David F. McDermott, MD - Beth israel Deconess Medical Center
Tanya B. Dorff, MD - City of Hope
Jeannie Hoffman-Censits, MD - Johns Hopkins
Lisa Holle, PharmD, BCOP, FHOPA, FISOPP - UConn School of Pharmacy
Lidia P. Lopez, AGPCNP-BC - UCLA
Thomas Powles, MBBS, MD MRCP - Queen Mary University of London
Tracy Rose, MD, MPH - University of North Carolina at Chapel Hill
Virginia Seery, MSN, RN, AMP-BC, AOCNP - Beth Israel Deconess Medical Center
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify the cancer immunotherapy approaches in use for the treatment of genitourinary cancers.
- Summarize recent updates in cancer immunotherapy for genitourinary cancers including emerging toxicities and management.
- Implement cancer immunotherapy for genitourinary cancer into clinical practice appropriately.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-102-H01-P)
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: October 27, 2021
|
Approved Credit: : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ANCC: 3.75 hours Contact HourACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™ACPE: 3.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| | MORE INFO |
|
|
